Akebia's Vadadustat Misses In Non-Dialysis CKD, But Filings Still Planned For 2021
HIF-PHI inhibitor failed to show non-inferiority to ESAs in the primary cardiovascular safety endpoint of a Phase III program for the treatment of anemia due to chronic kidney disease.
You may also be interested in...
AstraZeneca's partner FibroGen stunned investors and regulators by announcing that previously disclosed cardiovascular safety data for CKD candidate roxadustat included changes made post hoc, rather than as pre-specified with the US FDA.
AstraZeneca is in pole position to open up the HIF-PH inhibitor market – but GSK has a rival in the wings.
Dermatology, chronic kidney disease and liver disease therapies stand out in a crowd of user fee goals that is actually bigger than at the same point in 2020.